127 related articles for article (PubMed ID: 35464538)
1. The Pattern of Thyroid Malignancy and Its Associated Characteristics Among United Arab Emirates Population With More Focus on Patients in the Bethesda III Category.
Kiblawi MA; Hafeez K; Lami SK; Al Teneiji OA; Al Mubarak AN; Swaid TK; Ahmed SA; Alabiri RS; Alabiri RS
Cureus; 2022 Mar; 14(3):e23321. PubMed ID: 35464538
[TBL] [Abstract][Full Text] [Related]
2. Ultrasound-guided fine needle aspiration cytology and ultrasound examination of thyroid nodules in the UAE: A comparison.
Al-Salam S; Sharma C; Abu Sa'a MT; Afandi B; Aldahmani KM; Al Dhaheri A; Yahya H; Al Naqbi D; Al Zuraiqi E; Mohamed BK; Almansoori SA; Al Zaabi M; Al Derei A; Al Shamsi A; Kaabi JA
PLoS One; 2021; 16(4):e0247807. PubMed ID: 33826647
[TBL] [Abstract][Full Text] [Related]
3. Malignancy rates in thyroid nodules classified as Bethesda categories III and IV; a subcontinent perspective.
Zahid A; Shafiq W; Nasir KS; Loya A; Abbas Raza S; Sohail S; Azmat U
J Clin Transl Endocrinol; 2021 Mar; 23():100250. PubMed ID: 33643850
[TBL] [Abstract][Full Text] [Related]
4. Improving Malignancy Prediction in AUS/FLUS Pediatric Thyroid Nodules with the Aid of Ultrasound.
Arora S; Khoury J; Trout AT; Chuang J
Horm Res Paediatr; 2020; 93(4):239-244. PubMed ID: 32894855
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience.
Almahari SA; Harb Z; Alshaikh S
Cytojournal; 2019; 16():18. PubMed ID: 31576199
[TBL] [Abstract][Full Text] [Related]
6. Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS).
Mulita F; Plachouri MK; Liolis E; Vailas M; Panagopoulos K; Maroulis I
Endokrynol Pol; 2021; 72(2):143-144. PubMed ID: 33749812
[TBL] [Abstract][Full Text] [Related]
7. Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?
Yoo MR; Gweon HM; Park AY; Cho KE; Kim JA; Youk JH; Son EJ
PLoS One; 2015; 10(6):e0130138. PubMed ID: 26115096
[TBL] [Abstract][Full Text] [Related]
8. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
9. Prospective Study of Bethesda Categories III and IV Thyroid Nodules: Outcomes and Predictive Value of BRAF
Chirayath SR; Pavithran PV; Abraham N; Nair V; Bhavani N; Kumar H; Menon UV; Menon AS
Indian J Endocrinol Metab; 2019; 23(3):278-281. PubMed ID: 31641627
[TBL] [Abstract][Full Text] [Related]
10. Thyroid malignancy among patients with thyroid nodules in the United Arab Emirates: a five-year retrospective tertiary Centre analysis.
Alseddeeqi E; Baharoon R; Mohamed R; Ghaith J; Al-Helali A; Ahmed LA
Thyroid Res; 2018; 11():17. PubMed ID: 30519286
[TBL] [Abstract][Full Text] [Related]
11. Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital.
Al Dawish M; Alwin Robert A; Al Shehri K; Hawsawi S; Mujammami M; Al Basha IA; Alrasheed M; Asiri S; Alzouman M; Alkharashi E
Cureus; 2020 May; 12(5):e8202. PubMed ID: 32455091
[TBL] [Abstract][Full Text] [Related]
12. Follow-Up Strategies for Thyroid Nodules with Benign Cytology on Ultrasound-Guided Fine Needle Aspiration: Malignancy Rates of Management Guidelines Using Ultrasound Before and After the Era of the Bethesda System.
Yoon JH; Lee HS; Kim EK; Moon HJ; Park VY; Kwak JY
Thyroid; 2019 Sep; 29(9):1227-1236. PubMed ID: 31359839
[No Abstract] [Full Text] [Related]
13. Association of patient characteristics, ultrasound features, and molecular testing with malignancy risk in Bethesda III-V thyroid nodules.
Talmor G; Badash I; Zhou S; Kim YJ; Kokot NC; Hsueh W; Chambers T
Laryngoscope Investig Otolaryngol; 2022 Aug; 7(4):1243-1250. PubMed ID: 36000058
[TBL] [Abstract][Full Text] [Related]
14. Thyroid nodules with indeterminate cytopathology: a constant challenge in everyday practice. The effectiveness of clinical decisions using diagnostic tools available in Poland.
Kotecka-Blicharz A; Pfeifer A; Czarniecka A; Oczko-Wojciechowska M; Nożyńska E; Chmielik E; Jarząb M; Jarząb B; Krajewska J
Pol Arch Intern Med; 2021 Dec; 131(12):. PubMed ID: 34633157
[TBL] [Abstract][Full Text] [Related]
15. Thyroid Nodule Management: Thyroid-Stimulating Hormone, Ultrasound, and Cytological Classification System for Predicting Malignancy.
Al Dawish MA; Alwin Robert A; Thabet MA; Braham R
Cancer Inform; 2018; 17():1176935118765132. PubMed ID: 29581701
[TBL] [Abstract][Full Text] [Related]
16. Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center.
Godoi Cavalheiro B; Kober Nogueira Leite A; Luongo de Matos L; Palermo Miazaki A; Marcel Ientile J; Aurelio V Kulcsar M; Roberto Cernea C
Int J Endocrinol Metab; 2018 Jan; 16(1):e12871. PubMed ID: 29696036
[TBL] [Abstract][Full Text] [Related]
17. Cytological Sub-Classification of Atypia of Undetermined Significance May Predict Malignancy Risk in Thyroid Nodules.
Elomami A; Elhag SA; Alseddeeqi E
Acta Cytol; 2021; 65(3):205-212. PubMed ID: 33524971
[TBL] [Abstract][Full Text] [Related]
18. Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS).
Ho AS; Sarti EE; Jain KS; Wang H; Nixon IJ; Shaha AR; Shah JP; Kraus DH; Ghossein R; Fish SA; Wong RJ; Lin O; Morris LG
Thyroid; 2014 May; 24(5):832-9. PubMed ID: 24341462
[TBL] [Abstract][Full Text] [Related]
19. Impact of Ultrasonographic Features for Thyroid Malignancy in Patients With Bethesda Categories III, IV, and V: A Retrospective Observational Study in a Tertiary Center.
Hacim NA; Akbaş A; Ulgen Y; Aktokmakyan TV; Meric S; Tokocin M; Karabay O; Altinel Y
Cureus; 2021 Jul; 13(7):e16708. PubMed ID: 34466333
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and associated malignancy of Bethesda category III cytologies of thyroid nodules assigned to the "cytological atypia" or "architectural atypia" groups.
García Pascual L; Surralles ML; Morlius X; Garcia Cano L; González Mínguez C
Endocrinol Diabetes Nutr (Engl Ed); 2018 Dec; 65(10):577-583. PubMed ID: 30262240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
